Susceptibility of Motor-Evoked Potentials to Varying Targeted Blood Levels of Dexmedetomidine

Phase 1

Completed

Interventions: Drug: low dexmedetomidine, low propofol
Drug: high dexmedetomidine, low propofol
Drug: Dexmedetomidin
Drug: Dexmedetomidine

Brief Summary: Reduction of the spinal cord injuries during scoliosis surgery is a major goal of the anesthesia and surgical team. Despite improvement in scoliosis surgery over the years, the development of neurological deficits remains the most feared complication of spine surgery. During scoliosis surgery it is very important to monitor the spinal cord to detect spinal cord injury with surgical manipulation. Continuous or intermittent intraoperative electrophysiological monitoring (neuron-monitoring) is used routinely during these procedures to provide the surgeon with information concerning the integrity of neurological structures at risk. All neuron-monitoring modalities are affected by the anesthetic regimen used. Of the various intravenous anesthetic drugs, the combination of propofol, remifentanil and dexmedetomidine appear to impact neuron-monitoring the least. The current anesthetic practice is to use the three drugs in combination at doses that do not depress the signals but there is no data relating targeted dexmedetomidine and propofol blood levels to neuron-monitoring signals. The lack of data results in wide variability in dosing with consequent variability in patient response.

Hypothesis: Clinically relevant blood levels of dexmedetomidine will affect the amplitude of transcranial motor-evoked potentials (TcMEP) either independently or by interaction with propofol in a dose dependent manner.

Recruitment & Eligibility

Inclusion Criteria

Subjects must be 10 to 25 years of age
Diagnosis of idiopathic scoliosis is established
Subject's legal authorized representative has given written, informed consent to participate in the study and, where appropriate, the subject has given assent to participate
American society of Anesthesiology physical status one/two
Patients scheduled for posterior spinal fusion only

Exclusion Criteria

• Patients with neuromuscular scoliosis and patients with motor or sensory deficit in the lower extremities
- Patients with allergy to, or contraindication for the drugs or techniques used in the study
- Morbid obesity (Body mass index higher than 40)
- History of malignant hyperthermia
- Patient with severe cardiopulmonary disease (pulmonary hypertension, cardiomyopathy, mechanical ventilation)

Arm && Interventions

Group	Intervention	Description
I	low dexmedetomidine, low propofol	Dexmedetomidine low infusion, Propofol low infusion
II	high dexmedetomidine, low propofol	Dexmedetomidine high infusion, Propofol low infusion
IV	Dexmedetomidin	Dexmedetomidine high infusion, Propofol high infusion
V	Dexmedetomidine	Dexmedetomidine intermediate infusion, Propofol intermediate infusion
III	Dexmedetomidine	Dexmedetomidine low infusion, Propofol high infusion

Primary Outcome Measures

Name	Time	Method
Motor Evoked Potential Amplitude	baseline, 30 minutes	The primary outcome measure of the study was the participants who had Motor Evoked Potentials Amplitude significantly reduced (more than 70%)compared to the baseline.

Secondary Outcome Measures